The Effect of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease

Phase 2 Completed 180 enrolled Beijing Konruns Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This phase II trial attempts to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease.

Timeline

Start: 2021-01-19
Primary completion: 2021-11-30
Completion: 2021-11-30

Outcome

Met primary endpoint

paper points in the placebo, ZY5301 300 mg/d, and ZY5301 600 mg/d groups, respectively (P < .001). PMID 39042407 ↗

Publications

Teng X, Li H, Yang D, Gao Z, Cui L, Chen H, Song Q, Xu L, Li H, Zhang Q, Wu J, Leng J. ZY5301 Tablet vs Placebo for Treatment of Chronic Pelvic Pain After Pelvic Inflammatory Disease: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2024 Jul 1;7(7):e2423229. doi: 10.1001/jamanetworkopen.2024.23229.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Jincaopian Tablets	Traditional medicine (herbal / TCM)	0.1 g	Oral
Subject	Jincaopian Tablets	Traditional medicine (herbal / TCM)	0.2 g	Oral